TriangleNCT00559273 · CITED IN SOURCE DOCUMENTS
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2016-11-01
This study will compare the efficacy and safety of subcutaneous Mircera and subcutaneous darbepoetin in the treatment of renal anemia in participants with chronic kidney disease who are not on dialysis and not receiving erythropoiesis-stimulating agents (ESA). Participants will be randomized to receive either Mircera once every 4 weeks, at a starting dose of 1.2 micrograms/kilogram (mcg/kg), or darbepoetin alfa once weekly, at a starting dose of 0.45 mcg/kg (or once every two weeks, 0.75 mcg/kg). The anticipated time on study treatment is 3-12 months.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Percentage of Participants With Hemoglobin (Hb) Response
Change in Hemoglobin (Hb) Concentration Between Baseline and Evaluation Period
Hemoglobin (Hb) Concentration Over the Time
Time to Hemoglobin Response
Percentage of Participants With Red Blood Cell (RBC) Transfusions
Percentage of Participants Who Had at Least 1 Hemoglobin Value Exceeding 12.0 g/dL
Percentage of Participants With Stable Hemoglobin Response
Percentage of Participants Who Required Dose Adjustments to Achieve a Stabilized Response
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Participants with chronic kidney disease (CKD) stage 3 (creatinine clearance \[CrCl\]/ glomerular filtration rate \[GFR\] 30 to 59 milliliter per minutes per 1.73 meter square \[mL/min/1.73m\^2\]) or Stage 4 (CrCl/GFR 15-29 mL/min/1.73m\^2) who did not require dialysis. CrCl/GFR was estimated with the Cockcroft-Gault equation or the abbreviated Modification of Diet in Renal Disease (MDRD) equation * Anemia defined as baseline Hb concentration less than (\<) 10.5 gram per deciliter (g/dL) Exclusion Criteria: * Previous therapy with any ESA within 12 weeks prior to screening * Renal allograft in place * Immunosuppressive therapy in the 12 weeks prior to screening * Overt gastrointestinal bleeding and red blood cells (RBC) transfusions within 8 weeks before screening
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Participants will receive Mircera (Methoxy polyethylene glycol-epoetin beta), administered subcutaneously (SC) at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.
- intervention Names
- Drug: Methoxy polyethylene glycol-epoetin beta
- label
- Mircera
- type
- EXPERIMENTAL
- description
- Participants will receive darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.
- intervention Names
- Drug: Darbepoetin alfa
- label
- Darbepoetin Alfa
- type
- ACTIVE_COMPARATOR
- interventions
- arm Group Labels
- Mircera
- description
- 1.2 mcg/kg SC monthly, starting dose
- name
- Methoxy polyethylene glycol-epoetin beta
- other Names
- Mircera
- RO0503821
- type
- DRUG
- arm Group Labels
- Darbepoetin Alfa
- description
- 0.45 mcg/kg SC weekly or 0.75 mcg/kg every 2 weeks, starting dose
- name
- Darbepoetin alfa
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 307
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Hb response was an observed increase in Hb greater than or equal to (\>=) 1.0 gram per deciliter (g/dL) from baseline and an Hb concentration \>= 10.0 g/dL before the end of the study without red blood cells (RBC) transfusion before response.
- measure
- Percentage of Participants With Hemoglobin (Hb) Response
- time Frame
- Baseline up to Week 28
- description
- A time adjusted average baseline Hb concentration was calculated using the trapezoid rule from all available Hb measurements taken during the baseline period. The average evaluation period Hb concentration for each individual was calculated using the same method, from all their available measurements taken during the 2 month evaluation period (Week 21 to 28). The change in Hb concentration between the baseline and evaluation period was calculated by subtracting the baseline Hb from the evaluation period Hb. All blood samples for Hb measurements were taken prior to study drug administration.
- measure
- Change in Hemoglobin (Hb) Concentration Between Baseline and Evaluation Period
- time Frame
- Baseline (measurements at Week -2, Week -1 and Day 1) and Evaluation Period (Week 22, Week 24, Week 26, Week 28)
- secondary Outcomes
- description
- The hemoglobin concentration was measured in g/dL every 2 weeks and at final visit.
- measure
- Hemoglobin (Hb) Concentration Over the Time
- time Frame
- Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and final visit (Week 29)
- description
- Time to Hb response is defined as the number of study days until the first occurrence of an Hb response. Participants without events were censored at the time of evaluation. Median and 95 percent (%) confidence interval (CI) were estimated using Kaplan-Meier Survival Analysis. Hb response was an observed increase in Hb \>=1.0 g/dL from baseline and an Hb concentration \>= 10.0 g/dL before the end of the study without RBC transfusion before response.
- measure
- Time to Hemoglobin Response
- time Frame
- Baseline up to Week 28
- description
- The percentage of participants who received RBC transfusions during the titration and evaluation periods were reported.
- measure
- Percentage of Participants With Red Blood Cell (RBC) Transfusions
- time Frame
- Baseline up to Week 28
- description
- Percentage of participants having at least one Hb value greater than (\>) 12 g/dL during the first 8 weeks of the study was reported.
- measure
- Percentage of Participants Who Had at Least 1 Hemoglobin Value Exceeding 12.0 g/dL
- time Frame
- Baseline to Week 8
- description
- A participant was defined as having achieved a stable Hb response, if at least 75 percent (%) of the scheduled Hb values were between 10.0 g/dL and 12.0 g/dL and \>=1.0 g/dL from baseline for any 8-week time period, regardless of the requirement for dose adjustment for Hb maintenance. Achievement of stable response was determined using a moving 8-week time window, moving forward by 14 days in each iteration starting at Day 15, searching to see if the following conditions were met: 1) At least 3 scheduled Hb values (75% of the scheduled Hb values) in any 8-week time window were \>=1.0 g/dL from baseline (as calculated above) and within the range of 10.0 g/dL to 12.0 g/dL. 2). There were at least 3 recorded Hb values within the time window.
- measure
- Percentage of Participants With Stable Hemoglobin Response
- time Frame
- Baseline to Week 28
- description
- The total number of dose adjustments needed to achieve stabilized response was calculated from Day 1 until the first 8-week time window in which response was achieved. A participant was defined as having achieved a stable Hb response, if at least 75% of the scheduled Hb values were between 10.0 g/dL and 12.0 g/dL and \>=1.0 g/dL from baseline for any 8-week time period, regardless of the requirement for dose adjustment for Hb maintenance. Achievement of stable response was determined using a moving 8-week time window, moving forward by 14 days in each iteration starting at Day 15, searching to see if the following conditions were met: 1) At least 3 scheduled Hb values (75% of the scheduled Hb values) in any 8-week time window were \>=1.0 g/dL from baseline (as calculated above) and within the range of 10.0 g/dL to 12.0 g/dL. 2) There were at least 3 recorded Hb values within the time window.
- measure
- Percentage of Participants Who Required Dose Adjustments to Achieve a Stabilized Response
- time Frame
- Baseline to Week 28
Full study description
- brief Summary
- This study will compare the efficacy and safety of subcutaneous Mircera and subcutaneous darbepoetin in the treatment of renal anemia in participants with chronic kidney disease who are not on dialysis and not receiving erythropoiesis-stimulating agents (ESA). Participants will be randomized to receive either Mircera once every 4 weeks, at a starting dose of 1.2 micrograms/kilogram (mcg/kg), or darbepoetin alfa once weekly, at a starting dose of 0.45 mcg/kg (or once every two weeks, 0.75 mcg/kg). The anticipated time on study treatment is 3-12 months.
Source references
- references
- citation
- Chung EY, Palmer SC, Saglimbene VM, Craig JC, Tonelli M, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2023 Feb 13;2(2):CD010590. doi: 10.1002/14651858.CD010590.pub3.
- pmid
- 36791280
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-5ed4cfc0ca5ce9ad2cbb
- requested nct id
- NCT00559273
- primary nct id
- NCT00559273
- source kind
- fda_spl_label
- source record id
- 0a85c353-f0fe-4bdb-843e-47264785e209
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- payload sha256
- 211f9a6142ee3f8319e84665d293ce7a83e505a86a6b17279294dbf6eab080dc
- payload
- application numbers
- BLA125164
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-5ed4cfc0ca5ce9ad2cbb
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00559273
- occurrences
- context exact
- .5 Darbepoetin alfa (n=162) 96 (92, 99) 2.0 6.8 Study 2 Mircera (n=135) 93 (88, 97) 2.7 5.2 Epoetin alfa/beta (n=46) 91 (79, 98) 2.6 4.3 In the CORDATUS trial (NCT00559273), a randomized controlled study in patients with CKD not on dialysis and not currently treated with an ESA, Mircera, administered once monthly, was compared to
- end
- 5052
- exact text
- NCT00559273
- start
- 5041
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00000.json
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source json pointer
- /results/28/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 0a85c353-f0fe-4bdb-843e-47264785e209
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- e4718f278666e7868a115a8a0f136678de33f62f724c24f18a669c8edfd02a7c
- spl effective time
- 20260814
- spl set id
- 22c56f2a-f73c-60e7-e054-00144ff88e88
Preserved source evidence · Not medical advice